Evidence map›Paper›PMID 41939918›Full record

ArticleFrontiers in immunology2026

ATAD2 drives immunotherapy resistance by promoting lactic acid-mediated CD8

Wanfeng Gao, Jialei Xu, Yue Li, Jingchang Zhang, Chenghao Ma, Junfeng Chen, Jiajing Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wanfeng GaoState Key Laboratory of Medicinal Chemical Biology, Institute of Immunology, College of Life Sciences, Nankai University, Tianjin, China.
Jialei XuState Key Laboratory of Medicinal Chemical Biology, Institute of Immunology, College of Life Sciences, Nankai University, Tianjin, China.
Yue LiCollege of Medicine, Nankai University, Tianjin, China.
Jingchang ZhangTianjin Nankai Hospital, Tianjin Medical University, Tianjin, China.
Chenghao MaTianjin Nankai Hospital, Tianjin Medical University, Tianjin, China.
Junfeng ChenTianjin University Central Hospital, Tianjin University, Tianjin, China.
Jiajing ChenTianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Tianjin Institute of Hepatobiliary Disease, Central Hospital, Tianjin University/Tianjin Third Central Hospital, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: T cell-based immunotherapies have improved outcomes in lung adenocarcinoma (LUAD), yet many patients develop primary or acquired resistance. Tumor-intrinsic mechanisms that suppress CD8 Methods: Public LUAD transcriptomic datasets were analyzed to assess the association of ATPase family AAA domain-containing protein 2 (ATAD2) with prognosis and immune infiltration. Results: ATAD2 was significantly upregulated in LUAD and correlated with poor survival and decreased CD8 Conclusions: ATAD2 drives immunotherapy resistance in LUAD by activating an ATAD2-LDHA-LA axis that impairs CD8

Indexed as

Adenocarcinoma of LungATPases Associated with Diverse Cellular ActivitiesCD8-Positive T-LymphocytesDNA-Binding ProteinsDrug Resistance, NeoplasmLactic AcidLung NeoplasmsAnimalsCell Line, TumorHumansImmunotherapyMiceATAD2 protein, humanATPases Associated with Diverse Cellular ActivitiesDNA-Binding ProteinsLactic AcidATAD2lactic acidLDHAlung adenocarcinomaT cell therapy resistance

Identifiers

PMID41939918
PMCPMC13044016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.